UY35818A - Composiciones y métodos para modular los receptores x farnesoides - Google Patents

Composiciones y métodos para modular los receptores x farnesoides

Info

Publication number
UY35818A
UY35818A UY0001035818A UY35818A UY35818A UY 35818 A UY35818 A UY 35818A UY 0001035818 A UY0001035818 A UY 0001035818A UY 35818 A UY35818 A UY 35818A UY 35818 A UY35818 A UY 35818A
Authority
UY
Uruguay
Prior art keywords
farnesoid
receptors
compositions
modulate
methods
Prior art date
Application number
UY0001035818A
Other languages
English (en)
Spanish (es)
Inventor
Chianelli Donatella
Nelson John
Paul Vincent Rucker
David C Tully
Molteni Valentina
Liu Xiaodong
Jason Thomas Roland
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51982773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35818(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of UY35818A publication Critical patent/UY35818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
UY0001035818A 2013-11-05 2014-11-04 Composiciones y métodos para modular los receptores x farnesoides UY35818A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361900013P 2013-11-05 2013-11-05

Publications (1)

Publication Number Publication Date
UY35818A true UY35818A (es) 2015-05-29

Family

ID=51982773

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035818A UY35818A (es) 2013-11-05 2014-11-04 Composiciones y métodos para modular los receptores x farnesoides

Country Status (42)

Country Link
US (5) US9682939B2 (enExample)
EP (1) EP3065738B1 (enExample)
JP (1) JP6424231B2 (enExample)
KR (1) KR102350357B1 (enExample)
CN (1) CN105682656B (enExample)
AP (1) AP2016009165A0 (enExample)
AR (1) AR098316A1 (enExample)
AU (1) AU2014346919B2 (enExample)
BR (1) BR112016009630B1 (enExample)
CA (1) CA2927705C (enExample)
CL (1) CL2016000982A1 (enExample)
CR (1) CR20160212A (enExample)
CU (1) CU24375B1 (enExample)
CY (1) CY1120273T1 (enExample)
DK (1) DK3065738T3 (enExample)
EA (1) EA030430B1 (enExample)
ES (1) ES2670984T3 (enExample)
GT (1) GT201600085A (enExample)
HR (1) HRP20180817T1 (enExample)
HU (1) HUE039155T2 (enExample)
IL (1) IL245242B (enExample)
JO (1) JO3454B1 (enExample)
LT (1) LT3065738T (enExample)
MA (1) MA39088B1 (enExample)
MX (1) MX364834B (enExample)
MY (1) MY175903A (enExample)
NO (1) NO3105103T3 (enExample)
NZ (1) NZ719078A (enExample)
PE (1) PE20160682A1 (enExample)
PH (1) PH12016500777B1 (enExample)
PL (1) PL3065738T3 (enExample)
PT (1) PT3065738T (enExample)
RS (1) RS57179B1 (enExample)
SG (1) SG11201603026PA (enExample)
SI (1) SI3065738T1 (enExample)
SV (1) SV2016005192A (enExample)
TN (1) TN2016000143A1 (enExample)
TR (1) TR201807321T4 (enExample)
TW (1) TWI662027B (enExample)
UY (1) UY35818A (enExample)
WO (1) WO2015069666A1 (enExample)
ZA (1) ZA201602555B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
JP6424231B2 (ja) 2013-11-05 2018-11-14 ノバルティス アーゲー ファルネソイドｘ受容体をモジュレートするための組成物および方法
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
US10351576B2 (en) 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors
CN108697702A (zh) 2016-02-22 2018-10-23 诺华股份有限公司 使用fxr激动剂的方法
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
SI3730487T1 (sl) 2016-06-13 2022-08-31 Gilead Sciences, Inc. Azetidinski derivati kot modulatorji FXR (NR1H4)
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
WO2018051229A1 (en) * 2016-09-14 2018-03-22 Novartis Ag Novel regimes of fxr agonists
RU2019113150A (ru) * 2016-10-05 2020-11-06 Новартис Аг Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
KR102743630B1 (ko) 2017-03-28 2024-12-18 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
AU2018279609B2 (en) * 2017-06-05 2022-01-27 Bangalore University Compounds useful in inhibiting human trefoil factor 3
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019053582A1 (en) * 2017-09-13 2019-03-21 Novartis Ag COMBINATIONS HAVING FXR AGONISTS
JP2021502364A (ja) 2017-11-09 2021-01-28 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
FI3911647T3 (fi) 2019-01-15 2024-03-01 Gilead Sciences Inc Isoksatsoliyhdiste fxr-agonistina ja sitä käsittäviä lääkekoostumuksia
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
CA3159163A1 (en) 2020-01-15 2021-07-22 Raphael Darteil Use of fxr agonists for treating an infection by hepatitis d virus
CN113387828A (zh) * 2020-03-14 2021-09-14 江巨东 一种阿利克仑中间体的制备方法
WO2022037663A1 (zh) * 2020-08-21 2022-02-24 苏州晶云药物科技股份有限公司 苯甲酸衍生物的新晶型及其制备方法
WO2022152770A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CA3265777A1 (en) * 2022-08-26 2024-02-29 Celmatix Inc. NEW FSHR MODULATORS AND THEIR USES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
AU2007267606A1 (en) * 2006-05-24 2007-12-06 Eli Lilly And Company FXR agonists
BRPI0716901B1 (pt) * 2006-09-15 2020-04-22 Thales Avionics Inc sistema para transferir conteúdo e método para entregar conteúdo entre um veículo e outra entidade
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
JP6424231B2 (ja) 2013-11-05 2018-11-14 ノバルティス アーゲー ファルネソイドｘ受容体をモジュレートするための組成物および方法
US10351576B2 (en) 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors

Also Published As

Publication number Publication date
KR20160079091A (ko) 2016-07-05
RS57179B1 (sr) 2018-07-31
MY175903A (en) 2020-07-15
SI3065738T1 (en) 2018-06-29
NZ719078A (en) 2018-07-27
ZA201602555B (en) 2017-06-28
MX364834B (es) 2019-05-08
IL245242B (en) 2019-03-31
LT3065738T (lt) 2018-05-10
PH12016500777A1 (en) 2016-05-30
PE20160682A1 (es) 2016-07-23
US11021446B2 (en) 2021-06-01
DK3065738T3 (en) 2018-06-06
CN105682656B (zh) 2019-11-05
CA2927705A1 (en) 2015-05-14
IL245242A0 (en) 2016-06-30
HUE039155T2 (hu) 2018-12-28
JP6424231B2 (ja) 2018-11-14
US20170275256A1 (en) 2017-09-28
SV2016005192A (es) 2016-11-21
KR102350357B1 (ko) 2022-01-14
TN2016000143A1 (en) 2017-10-06
WO2015069666A1 (en) 2015-05-14
BR112016009630B1 (pt) 2021-02-09
CN105682656A (zh) 2016-06-15
SG11201603026PA (en) 2016-05-30
CA2927705C (en) 2021-09-21
JO3454B1 (ar) 2020-07-05
EA030430B1 (ru) 2018-08-31
EA201690930A1 (ru) 2016-08-31
US20160340317A1 (en) 2016-11-24
US20200247757A1 (en) 2020-08-06
AR098316A1 (es) 2016-05-26
GT201600085A (es) 2019-07-19
CU20160063A7 (es) 2016-09-30
PL3065738T3 (pl) 2018-07-31
MA39088B1 (fr) 2018-06-29
CL2016000982A1 (es) 2016-10-07
EP3065738A1 (en) 2016-09-14
PH12016500777B1 (en) 2016-05-30
US9682939B2 (en) 2017-06-20
US20190062283A1 (en) 2019-02-28
US10683271B2 (en) 2020-06-16
ES2670984T3 (es) 2018-06-04
MA39088A1 (fr) 2017-07-31
US20210253534A1 (en) 2021-08-19
NO3105103T3 (enExample) 2018-05-12
JP2016535784A (ja) 2016-11-17
AU2014346919A1 (en) 2016-05-12
CY1120273T1 (el) 2019-07-10
TR201807321T4 (tr) 2018-06-21
TW201612163A (en) 2016-04-01
HRP20180817T1 (hr) 2018-06-29
TWI662027B (zh) 2019-06-11
CR20160212A (es) 2016-07-22
CU24375B1 (es) 2018-12-05
EP3065738B1 (en) 2018-02-28
AU2014346919B2 (en) 2017-02-02
AP2016009165A0 (en) 2016-04-30
US10077240B2 (en) 2018-09-18
PT3065738T (pt) 2018-06-04
MX2016005865A (es) 2016-07-13
BR112016009630A8 (pt) 2020-04-07

Similar Documents

Publication Publication Date Title
UY35818A (es) Composiciones y métodos para modular los receptores x farnesoides
UY33815A (es) Composiciones y métodos para modular el fxr
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
UY35143A (es) Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
DOP2017000034A (es) Compuestos de imidazopiridazina
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
CR20140325A (es) Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2-
ECSP22007557A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
ECSP14011505A (es) Derivados de bencil sulfonamida útiles como inhibidores de mogat-2

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220307